415 Capital

LOS GATOS, Calif., Feb. 28, 2022 /PRNewswire/ — Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced today the closing of $30M in Series C financing. Led by Cormorant Asset Management and The Capital Partnership (TCP), with participation from 415 CAPITAL, AMED Ventures, PA MedTech VC Fund and Shifamed angel investors, the funds will be used to finalize product development and initiate a

Lausanne/Austin/Munich, 26 January 2022: Distalmotion announced today the closing of a USD 90 million Series E financing to support the global commercialization of its surgical robot Dexter. Revival Healthcare Capital (Revival) led the round with participation from 415 CAPITAL (415), as well as existing investors.

Aktiia’s automated Optical Blood Pressure Monitoring System for 24-7 use at the wrist reports accelerating sales growth in the United Kingdom, Ireland, Germany, Austria, Switzerland, France and Italy. The funds will be used to fuel growth in these markets and to obtain FDA clearance.

415 Capital offers a highly collaborative and entrepreneurial culture in which intellectual curiosity, initiative, passion and diligence are rewarded. We offer the opportunity to gain investment experience across the MedTech startup lifecycle (concept to market-leader) as well as the chance to make a real difference by working with exceptional entrepreneurs to bring breakthrough technologies to patients.

David Thompson is a Co-Founder, General Partner and serves as Chief Financial Officer of 415C. David has over 35 years of experience in corporate management, audit and finance, the last 25 years in the medical technology sector. He has invested in over 20 medical technology companies and co-founded and managed several European medical device distribution companies, including CoRRect Medical GmbH (acquired by Uniphar PLC in 2021), Regis Medical GmbH (merged with CoRRect Medical GmbH), Ovum Ventur

Eduardo Palma serves as Associate at 415C. He joined the firm in September 2021 and has supported multiple Due Diligence and financing processes. Eduardo holds a Bachelors’ of Engineering Science (Hons.) from the Technical University of Munich as well as a Masters’ Degree in Industrial Biotechnology .

Frank Groenewegen is a Co-Founder and the Chairman Emeritus of 415C. He brings almost 40 years of investing, management, sales & marketing experience in the medical technology space, the last 30 years as serial investor and entrepreneur. As an investor, Frank has funded over 40 companies. As an entrepreneur, he has founded, built, and exited several successful European medical device distribution companies, including CoRRect Medical (acquired by Uniphar PLC in 2021), Regis Medical GmbH (merged w

Frederik Groenewegen is a Co-Founder and General Partner of 415C. He has been an investor in more than a dozen of innovative medical technology companies and led the firm’s investments in Supira, CorFlow, Cardiac Success, Aktiia, Distalmotion, R3 Vascular and TRiCares. He currently serves as a Board Director at R3 Vascular and TRiCares. Prior to co-founding 415C, Frederik served as Business Development Manager at Regis Medical, a Germany based medical device distributor where he helped source an

415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. For over 30 years, our team has empowered exceptional entrepreneurs through the provision of capital, expertise, and market access. We exclusively invest in large unmet patient needs in chronic diseases, with an emphasis on cardio & neurovascular disorders, the worldwide leading causes of death and the largest cost driver in the global healthcare systems. Our mission is to

If you would like to submit a business plan or are interested in more information about 415C, please use the contact form below or sign up for our newsletter. The fields marked with (*) are mandatory and must be filled in.

415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. For over 25 years, our team has been providing exceptional entrepreneurs with capital, expertise, and market access.

415 Capital Fund II GmbH & Co.KG (hereinafter “415 Capital”, “we” or “us”), represented by 415 Capital Management GmbH & Co., in turn represented by its General Partners Mr. Frederik Groenewegen, Mr. David Thompson, and Mr. Frank Groenewegen, operates the domain www.415capital.com (the “Website”). 415 Capital protects the privacy of all Website users and strictly complies with all applicable data protection provisions, including the European General Data Protection Regulation (Datenschutzgrundve

415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. For over 25 years, our team has been providing exceptional entrepreneurs with capital, expertise, and market access.